Project Grant R01CA285395
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$749K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Boston, MA 02215, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $680,334 to the Icahn School of Medicine at Mount Sinai to conduct research aimed at elucidating the cellular and molecular mechanisms underlying age-associated inflammation and its impact on tumor progression. The research will utilize multi-omic profiling of myeloid cells and progenitors from young and aged patients, as well as complex bone marrow experiments, to define the central role...
The federal Project Grant award of $433,157 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Endeavor Health Clinical Operations, Northshore University Healthsystem Research Institute Division, supports research investigating the role of lipid-rich macrophages in the tumor microenvironment of prostate cancer. The study aims to determine whether altering the activity of certain enzymes and proteins involved in lipid metabolism and inflammatory signaling in these...
The National Cancer Institute (NCI) awarded a $942,442 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to the Dana-Farber Cancer Institute, Inc. (DFCI) to identify the mechanisms driving rapid evolution of cancer genomes. The research aims to understand the processes of "chromothripsis," a catastrophic mutational event that involves massive chromosome rearrangement, as well as "chromoplexy," another poorly understood mutational process...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $235,620.00 to the Albert Einstein College of Medicine to support research on novel therapeutics for preventing and treating inflammation-associated colorectal cancer. The key focus of this research is on the development and evaluation of MTDIA, a targeted inhibitor of the MTAP enzyme, and related prodrug compounds. The grant funding will support studies in two novel mouse...
This $1,062,474 federal Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research program) supports research by the Massachusetts Institute of Technology (MIT) to study the impact of DNA repair pathway interactions on the molecular and physiological consequences of methylation damage, with a focus on the carcinogenic effects of N-nitrosodimethylamine (NDMA). The key research objectives are to: 1) Test the mismatch repair (MMR) model by measuring the...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $444,569 to Beth Israel Deaconess Medical Center, Inc. to develop innovative models for hormone receptor positive (HR+) breast cancer using patient-derived organoids and cancer-associated fibroblasts. The goal is to address the lack of representative preclinical models for recurrent and metastatic HR+ breast cancer, which accounts for the majority of breast cancer deaths. The...
The federal Project Grant award R01CA300788, provided by the National Cancer Institute (NCI) under the CFDA 93.396 Cancer Biology Research program, supports research on the relationship between inflammatory signaling in the leptomeninges (the membranes surrounding the brain and spinal cord) and the growth of leptomeningeal metastases, a lethal complication of cancer. The $730,398 award to the Sloan-Kettering Institute for Cancer Research will leverage the institute's collection of clinical...
The National Cancer Institute (NCI) awarded a $689,934 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA. The grant will fund a large genome-wide association study (GWAS) covering over 13,000 patients receiving immune checkpoint inhibitor (ICI) cancer treatments. The study aims to characterize the genetic architecture underlying immune-related adverse events (IRAEs) associated with ICIs, and...
The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded a $632,300 Project Grant (R01CA301488) to Carnegie Mellon University to develop an integrated ultrahigh-throughput 3D volumetric super-resolution imaging system. This system will combine a multiscale fluorescence mesoscope with magnify expansion microscopy to enable rapid, large-area 3D imaging with exceptional detail. The goal is to study the interactions between cancer and immune cells in situ using a genetically...
The National Cancer Institute awarded a 5-year, $483,706 Project Grant (CFDA 93.396 Cancer Biology Research) to The Trustees of the University of Pennsylvania to study the regulation of immune cells called tumor-associated macrophages (TAMs) in the tumor microenvironment. The research aims to elucidate how changes in the composition and activity of the mitochondrial enzyme complex IV in TAMs, driven by the expression of NDUFA4L3 and miR-147, modulate TAM function and anti-tumor immunity. The...